Navigation Links
Unigene to Present at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference

BOONTON, N.J., Feb. 27, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced the Company's Vice President of Research and Development, Nozer Mehta, Ph.D., will be presenting at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference being held at the Sheraton Miyako Hotel in Tokyo, Japan.

The TIDES Oligonucleotide and Peptide Conferences are the premier forums focused on oligonucleotide and peptide-based therapeutics, serving as an annual gathering point for the leading companies, academics and researchers in the field.  As a key industry opinion and thought leader, Dr. Mehta will address the conference attendees on topics of critical importance to the growth of peptide therapeutics.

Recent Advances in Routes of Delivery for Peptide Pharmaceuticals

Plenary keynote presentation

  • Given by: Nozer Mehta, Ph.D., Vice President of Research and Development for Unigene
  • Date & Time: Tuesday, February 28, at 4:30pm JST (Tuesday, February 28, at 2:30am EST)
  • Focus: Peptides in advanced stages of clinical development with oral or transdermal technologies

Clinical Development of a Solid Dosage Oral Formulation for the 32 Amino Acid Peptide Salmon Calcitonin

  • Given by: Nozer Mehta, Ph.D., Vice President of Research and Development for Unigene
  • Date & Time: Thursday, March 1, at 12:00pm JST (Wednesday, February 29, at 10:00pm EST)
  • Focus: Advantages of Unigene's oral delivery technology demonstrated in a Phase 3 clinical study for salmon calcitonin, including an improved variability profile and limited food effects on the biological activity of the peptide

"I welcome the opportunity to provide the attendees of AsiaTIDES with a comprehensive review of recent advancements in the delivery of peptides, most notably Unigene's validated and most clinically advanced oral peptide delivery technology platform, as well as the company's late-stage and feasibility oral peptide programs developed via our Peptelligence™ platform," said Dr. Mehta. "Advances in the delivery of peptide therapeutics, particularly oral peptide technologies, have the opportunity to redefine the treatment regimen and market for numerous debilitating, chronic conditions.  Given this opportunity, the pharmaceutical industry is directing increasing attention and resources to companies and institutions that are developing next-generation peptide compounds, making a conference like AsiaTIDES an extremely valuable scientific and business development event."

About Unigene Laboratories, Inc.:

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration

Media Contact:
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
212-827-0020 /

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unigene Announces Key Appointments as Biotechnologies Strategic Business Unit Continues to Grow in 2012
2. Unigene Laboratories Granted US Patent for Peptide-Based Technology for Treatment of Obesity
3. Unigene Provides 2012 Business Outlook
4. Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9
5. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
6. Unigene Strengthens Board with the Appointment of Walgreens Executive, Thomas J. Sabatino, Jr.
7. Unigene Reports Third Quarter 2011 Financial Results
8. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
9. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
10. Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicines 28th Annual Meeting
11. Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference
Post Your Comments:
(Date:11/30/2015)... MAPLE GROVE, Minn. and BASEL, ... Upsher-Smith Laboratories, Inc. (Upsher-Smith), through its wholly-owned ... for the further development of a novel, oral small ... cell-adhesion molecule that may be effective in the treatment ... Phase II clinical development. --> ...
(Date:11/30/2015)... TOKYO , 1 décembre 2015 ... plus grande exposition et conférence d,Asie ... médicaux et sur l,industrie manufacturière, se ... du 20 au 22 avril ... - Photo - ...
(Date:11/30/2015)... 1, 2015 ... "Endometriosis - Pipeline Review, H2 2015" market ... therapeutic pipeline of Endometriosis and helps enhance ... strategies to gain competitive advantage. It strengthens ... MOAs to produce first-in-class and best-in-class products. ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., December 1, 2015 ... price per sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) ... provides software engineering, infrastructure, as well as operations and sustainment support to the ...
(Date:12/1/2015)... Knoxville, TN (PRWEB) , ... December 01, 2015 ... ... Lessons from the Field for Effective Post-Affiliation Integration ,” addresses a main “pain ... fail to deliver the anticipated results, once a deal is signed. This ...
(Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit , ... control over customization, the possibilities are truly endless, all with a click of a ... position, vertical flip, horizontal flip, depth of field and more, all within Final Cut ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... on receiving the 2015 HSJ Acute Sector Innovation Award on November 18th. This ... patient care experience, and propose exciting enhancements to the medical landscape. , The ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... and Brooke Bennett are collaborating with brands across various categories through traditional and ... figures make up an elite group of Gold Medal Moms who can connect ...
Breaking Medicine News(10 mins):